Approximately 5% of all non-small-cell lung cancers (NSCLC) are anaplastic lymphoma kinase-positive (ALK-positive). This study aims to compare the safety and efficacy of alectinib with crizotinib as the first-line treatment in...
Read MoreMalignant pleural mesothelioma (MPM) is a cancer of the lining of the lungs, characterized by chest pain, shortness of breath, and dry cough. Nintedanib is a medication that targets various receptors and kinases that are...
Read MoreNon-small-cell lung carcinoma (NSCLC) is one of the most common types of lung cancers. The use of tyrosine kinase inhibitors (TKIs) is impeded by the emergence of the Thr790Met mutation in a majority of patients with epidermal...
Read More
This course discusses the key findings of five studies presented at the 2020 virtual Annual...
Read MoreAngiotensin-converting enzyme (ACE) inhibitors help lower your blood pressure by relaxing your veins and arteries. Recent evidence suggests that the use of ACE inhibitors may increase the risk of lung cancer. This study aims to...
Read More
Risk increases as more cigarettes are smoked According to the Office of Minority Health of the...
Read MoreOverall survival also extended with conjugate treatment In a small, phase II trial, patients with advanced gastric cancer were far more likely to respond to conjugate therapy with trastuzumab deruxtecan (Enhertu) than with...
Read More
New research was presented at AATS 2020, the virtual Annual Meeting of the American Association...
Read MoreThe most favorable treatments for advanced EGFR-mutant NSCLC are less indicated. Forty-one studies were eligible for this Bayesian network secondary analysis. For PFS, erlotinib (Erlo)+bevacizumab (Bev) (HR 0.26, 95% CrI:...
Read More